RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL) from its SEC filings: 2025 revenue $294.3 million (+64% vs the year before), net margin 125%, free cash flow $75.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $294.3 million |
| Revenue growth | +64% |
| Net income | $367.0 million |
| Net margin | 124.7% |
| Free cash flow | $75.7 million |
| Diluted EPS | $19.48 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -23% |
| Cash | $60.8 million |
| Long-term debt | $45.0 million |
| Share count, 1 year | +4% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.